No Prescription |
 |
 | ||
|
Asacol Enema Generic Mesalazine |
|
| ||
No Prescription » Prescription Drugs 2 » Asacol Enema Generic Mesalazine ASACOL contains the active ingredient mesalazine.ASACOL is used to treat and/or keep in remission (ie: not reoccur) inflammatory bowel diseases such as ulcerative colitis and Crohn's disease.ASACOL belongs to a group of medicines called anti-inflammatories. These medicines work by inhibiting inflammatory agents in the body. ASACOL works topically ie: it works on the surface of the intestinal tract and bowel with which it comes into contact. Buy Asacol Enema Generic Mesalazine and other Prescription Drugs 2 products online at Medstore. Buy Online at Medstore - Click Here!
About Asacol Enema Generic Mesalazine: Product Type: Prescription Drugs 2 Asacol Enema ( Generic Mesalazine ) Product Origin: EU (Turkey) This product is able to be sourced and supplied at excellent prices because of favourable cross border currency conversions. All products are authentic brand names and will include a product information insert in English. Medical Information: This medication is used to treat ulcerative colitis a type of bowel disease. It does not cure ulcerative colitis but it may decrease symptoms such as stomach pain diarrhea and rectal bleeding caused by irritation/swelling in the colon/rectum. Mesalamine is an aminosalicylate anti-inflammatory drug. It is believed to work by keeping your body from making certain natural chemicals that may cause pain and swelling. OTHER USES: This section contains uses of this drug that are not listed in the approved professional labeling for the drug but that may be prescribed by your health care professional. Use this drug for a condition that is listed in this section only if it has been so prescribed by your health care professional. This medication may also be used to treat Crohn's disease. How to use Asacol Oral: Take this medication by mouth with or without food usually 3 times daily or as directed by your doctor. Dosage is based on your medical condition and response to treatment. Swallow this medication whole. Do not crush chew or break the tablets. Doing so can keep the drug from being released properly into the colon. Use this medication regularly in order to get the most benefit from it. To help you remember use it at the same times each day. Tell your doctor if your condition persists or worsens. Asacol Oral is used to treat the following:Ulcerated Colon Ulcerative Colitis currently Without SymptomsAsacol Oral may also be used to treat:Crohn's Disease Generic Mesalazine 1g/100mL 100mL 3 x 100mL 6 x 100mL Generic Mesalazine Asacol Enema
View more Prescription Drugs 2 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
